MedPath

Aviation Portable Oxygen Delivery System

Not Applicable
Withdrawn
Conditions
Oxygen Delivery Systems at Altitude
Interventions
Device: Integra Pulse Portable- Continuous flow
Device: Integra Pulse Portable- Pneumatic pulsed flow
Registration Number
NCT03425409
Lead Sponsor
Duke University
Brief Summary

This study aims to investigate dose based oxygen delivery vs. continuous flow of oxygen during simulated altitude conditions as would be experienced after a loss of pressure during commercial aircraft flight. Testing will be performed at rest and during light exercise at a simulated altitude of 15,000 feet in a hypobaric chamber. Performance of the two oxygen delivery systems will be compared using oxygen saturation determined by pulse oximetry.

Detailed Description

Not available

Recruitment & Eligibility

Status
WITHDRAWN
Sex
All
Target Recruitment
Not specified
Inclusion Criteria
  • healthy volunteers
Read More
Exclusion Criteria
  • smoking
  • pregnancy
  • sickle cell trait
  • cardiovascular or pulmonary disease
  • significant ear or sinus problems that would prevent equalization during pressure change
  • estimated VO2peak <35 mL/kg per minute (males) or <30 mL/kg per minute (females)
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
SEQUENTIAL
Arm && Interventions
GroupInterventionDescription
Continuous FlowIntegra Pulse Portable- Continuous flowOxygen delivery at 4 liters per minute is the standard method
Pneumatic Pulsed FlowIntegra Pulse Portable- Pneumatic pulsed flowOxygen delivery using test method
Primary Outcome Measures
NameTimeMethod
Device performance, as measured by SpO2one minute

The same subject must complete both oxygen delivery system exposures for the data to be used in system performance analysis. Equivalence of the two oxygen delivery systems will be defined as the lack of statistically significant difference (N=20) in SpO2 during the last minute of exercise between the pulse and continuous flow oxygen delivery systems. Average minimum SpO2 over the last minute of the test period will be reported.

Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath